Table 3.
Univariate & multivariate analysis of risk factor for overall pulmonary toxicity
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| SHR | 95% CI | P-value | SHR | 95% CI | P-value | |
| Group | ||||||
| Reduced dose rate group | 1 (ref) | |||||
| Conventional dose rate group | 1.86 | 0.93–3.71 | 0.078 | 2.61 | 1.26–5.40 | 0.010 |
| Total dose (Gy) | 1.19 | 0.94–1.51 | 0.156 | 1.38 | 1.04–1.83 | 0.025 |
| Daily dose (Gy) | ||||||
| Daily dose < 3 | 1 (ref) | |||||
| Daily dose ≥3 | 0.67 | 0.36–1.25 | 0.205 | |||
| Women | 1.23 | 0.70–2.18 | 0.471 | – | – | – |
| Age at TBI (year) | 1.00 | 0.98–1.02 | 0.723 | – | – | – |
| Cancer type | ||||||
| ALL | 1 (ref) | |||||
| AML | 1.47 | 0.81–2.67 | 0.210 | – | – | – |
| Others | 1.17 | 0.56–2.44 | 0.682 | – | – | – |
| Unrelated donor | 1.22 | 0.70–2.10 | 0.482 | – | – | – |
| Conditioning regimen | ||||||
| Cyclophosphamide | 1 (ref) | |||||
| Cy + othera | 1.92 | 0.76–4.81 | 0.165 | 2.86 | 1.11–7.38 | 0.029 |
| Othersb | 1.06 | 0.40 – 2.81 | 0.911 | 1.60 | 0.54–4.73 | 0.394 |
| Prior chemotherapy regimens | ||||||
| 1 | 1 (ref) | |||||
| 2 | 0.61 | 0.29–1.30 | 0.200 | – | – | – |
| ≥ 3 | 1.32 | 0.69–2.52 | 0.409 | – | – | – |
P-by Fine-Gray
SHR Sub-hazard ratios, ALL Acute lymphoblastic leukemia, AML Acute myeloid leukemia, GVHD Graft-versus-host disease
a other: cytarabine, fludarabine, etoposide
b others: cytarabine/fludaraibine, busulfan/fludarabine/etoposide, melphalan, melphalan/fludarabine, thiotepa